Perspective Therapeutics, Inc. (CATX) is a Medical - Devices company in the Healthcare sector, currently trading at $4.25. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CATX = $12 (+187.1% upside).
Valuation: CATX trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.33.
Net income is $103M (loss), growing at -105.9%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+77 pp trend).
Balance sheet: total debt is $2M against $207M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.17 (strong liquidity). Debt-to-assets is 0.6%. Total assets: $267M.
Analyst outlook: 9 / 11 analysts rate CATX as buy (82%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 94/100 (Pass), Income ?/100 (Fail).
